Select committee: Health and Social Care Committee
16th Report - Drugs policy: medicinal cannabis
HC 1821
Published 3 July 2019
Health and Social Care Committee Drugs policy: medicinal cannabis inquiry Report on parliament.uk ↗
At a glanceGovernment response published 6 September 2019
The government's response
Summary written by Accountability Index from the government's response. It is not the government's own words.
The government's response sets out actions on communications, research, guidance and supply, and states that more research is required on clinical and cost effectiveness "before decisions on public funding can be made".
- On communications, it is "committed" to actions including expanded Gov.uk and NHS.uk information, and NHSE-I and DHSC "will work together to develop clear information for patients and patient groups"; it will "explore" using the Science and Media Centre.
- On research, NIHR has issued two calls; any successful applications from the second call "would be expected to start around Autumn 2020", and NIHR funding "is not ring-fenced".
- On guidance, NICE will "carefully consider all responses" to its draft guidelines "with a view to publishing final guidelines in November 2019"; HEE e-learning is intended to be updated "on at least a quarterly basis".
- On supply, it says "further work on establishing a stable UK supply will be undertaken", including scoping options for UK manufacturers.
What the committee recommended
No recommendations or conclusions have been extracted from this report. This is normal for correspondence and for special reports.
Sources
- 16th Report - Drugs policy: medicinal cannabis ↗The committee's report, HC 1821, parliament.uk
- Drugs policy: medicinal cannabis: Government Response to the Committee's Sixteenth Report ↗The government's response, 6 September 2019, parliament.uk